Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Lung Cancer (Amsterdam, Netherlands)|July 26, 2021
Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapyRomain-David Seban, Jean-Baptiste Assié, Etienne Giroux-Leprieur, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 7, 2024
Pre-treatment [18F]FDG PET/CT biomarkers for the prediction of antibody-drug conjugates efficacy in metastatic breast cancerRomain-David Seban, Laurence Champion, Alexandre De Moura, et al.
Annals of Nuclear Medicine|October 18, 2020
FDG-PET biomarkers associated with long-term benefit from first-line immunotherapy in patients with advanced non-small cell lung cancerRomain-David Seban, Jean-Baptiste Assie, Etienne Giroux-Leprieur, et al.
European Journal of Cancer (Oxford, England : 1990)|January 24, 2018
Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphomaLaurent Dercle, Samy Ammari, Romain-David Seban, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|December 1, 2025
Impact of neoadjuvant immunotherapy on postoperative complications in oncoplastic breast cancer surgeryCapucine Barjot, Thomas Gaillard, Romain-David Seban, et al.
Abdominal Radiology (New York)|April 14, 2019
The role of multimodal imaging in guiding resectability and cytoreduction in pancreatic neuroendocrine tumors: focus on PET and MRILaura Rozenblum, Fatima-Zohra Mokrane, Randy Yeh, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 25, 2020
Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4Romain-David Seban, Antoine Moya-Plana, Lara Antonios, et al.
Cancers|August 14, 2020
Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line PembrolizumabRomain-David Seban, Jean-Baptiste Assié, Etienne Giroux-Leprieur, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 23, 2019
Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitorsRomain-David Seban, Laura Mezquita, Arnaud Berenbaum, et al.
Oncoimmunology|May 10, 2019
Increased bone marrow SUVmax on 18F-FDG PET is associated with higher pelvic treatment failure in patients with cervical cancer treated by chemoradiotherapy and brachytherapyRomain-David Seban, Charlotte Robert, Laurent Dercle, et al.
Pageof 5